Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.
暂无分享,去创建一个
J. Rodman | W E Evans | J H Rodman | J Ochs | J Yalowich | G K Rivera | M Sunderland | R L Kavanagh | Marc Sunderland | Judith Ochs | Jack C. Yalowich | Ronald L. Kavanagh | William E. Evans | Gaston K. Rivera
[1] R. Aur,et al. VM‐26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia , 1980, Cancer.
[2] S L George,et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.
[3] J H Goldie,et al. Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.
[4] R. Day,et al. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. , 1986, Cancer research.
[5] R. Schilsky,et al. Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability , 1989, Clinical pharmacology and therapeutics.
[6] C. Begg,et al. VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474). , 1979, Cancer treatment reports.
[7] G. Rivera,et al. Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma. , 1977, Cancer treatment reports.
[8] D. W. Fry,et al. Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro. , 1982, Cancer research.